News | Radiation Oncology | June 12, 2017

MD Anderson and Convergent R.N.R. Ltd. Establish Alliance to Further Develop New Radiation Technology with Potentially Fewer Side Effects

The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new radiation technology aimed at reducing side effects of standard radiation including unwanted radiation to healthy tissue

The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy and radiosurgery option. MD Anderson will develop technologies to enhance and enable clinical implementation of CRnR’s X-ray lens system called Mercy Beam.

MD Anderson will further explore the system’s use in delivering tumor-killing radiation while limiting the dose to healthy and/or sensitive organs in head and neck and pediatric cancers as well as small tumors in various other cancers. The beam works by focusing intensity of kilo-voltage X-ray radiation (similar to those used in chest X-ray) at the tumor site while delivering little to no radiation to nearby organs. This is in contrast to current practices in radiotherapy where mega-voltage X-ray radiation is used to kill cancer tumors.

“We hope to establish whether this technology, which converges and focuses low-energy X-rays, has potential for clinical and patient care use,” said Mohammad Salehpour, Ph.D., professor of Radiation Physics at MD Anderson. “We also will test its efficacy in destroying cancer cells and develop treatment protocols and procedures using the technology.”

 The study will first look at the technology’s applicability for smaller tumors, with the goal of furthering its efficacy for larger tumors.

“This alliance will provide CRnR with an opportunity for development of low-energy converging X-ray beam technology for treating cancerous tumors,” said Ze’ev Harel, chief executive officer and founder of CRnR. “It has the potential to establish CRnR as a leader in treating small tumors, while still sparing sensitive adjacent organs. It would further facilitate the general ends of constructing hybrid operation rooms based on radiotherapy-supported surgery theatres, and providing much-needed radiotherapy in peripheral locations and in remote and rural clinics. This alliance could benefit the company, and enable speeding up the development by performing preclinical and clinical trials.”

As part of the alliance, CRnR will develop, and MD Anderson will assess, the effectiveness of an MLC-like collimator for CRnR’ s X-ray lens technology. CRnR will provide and install a research chamber in MD Anderson’s simulation lab, where simulation and pre-clinical research will determine the potential for a clinical-grade device. MD Anderson will build, equip and staff a simulation lab housing a research chamber provided by CRnR, and will receive payments based on market capitalization, milestones toward FDA approval, and royalties based on net sales for cancer treatments.

 

For more information: www.mdanderson.org

Related Content

Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Survey Examines Impact of Bundled Payments Ahead of Expected New CMS Programs
News | Business | October 12, 2017
According to a recent survey, participation in bundled payments has improved the quality of care, and anticipation and...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init